

Special Issue

Proton and Carbon Ion Therapy

Message from the Guest Editor

Proton therapy was introduced in the 1940s and carbon-ion therapy was started in the 1990s. Recently the particle therapy of protons and carbon ions has spread to many countries around the world. Compared to conventional radiation treatment with X-rays, there are clinical reports that particle therapy is more effective against: 1) malignant tumors with less X-ray sensitivity; 2) tumors close to vital organs; and 3) large tumors. In this Special Issue, we would like to discuss how particle therapy is employed for cancers that are difficult to treat with X-ray therapy, as well as possible future uses of this therapy and its current state of progress. It would also be beneficial to look into the efficacy of combining particle therapy with chemotherapy. If we are able to clarify the strong points of ion beam radiotherapy in this special edition, we can expect progress on differentiating the uses of proton therapy and carbon-ion therapy from X-ray radiotherapy. We also welcome advice from facilities that have experience with proton therapy and/or carbon-ion therapy to those medical institutions that are considering introducing it.

Guest Editor

Dr. Yoshio Hishikawa

Department of Radiology, Medipolis Proton Therapy and Research Center, Ibusuki, Japan

Deadline for manuscript submissions

closed (31 January 2018)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/10627

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)